Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 4
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
BRCA1/2 mutation
breast cancer · Small Molecule Inhibitor
BRCA1/2 mutation is flagged as manual review required because public trials show inclusion required evidence in 8 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: dMMR | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02326844 | https://clinicaltrials.gov/study/NCT01989546 | https://clinicaltrials.gov/study/NCT04090567 | https://clinicaltrials.gov/study/NCT03562832 | https://clinicaltrials.gov/study/NCT02163694 | https://clinicaltrials.gov/study/NCT02401347 | https://clinicaltrials.gov/study/NCT05378204 | https://clinicaltrials.gov/study/NCT06625515